Aminocaproic Acid (aminocaproic acid)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Aminocaproic acid, a synthetic lysine analog, is an antifibrinolytic agent.
Aminocaproic acid is a synthetic lysine derivative that is an inhibitor of fibrinolysis. The drug has been shown to inhibit the activation of plasminogen and the action of plasmin. Aminocaproic acid inhibits the binding of plasmin to fibrin by occupying the lysine-binding sites of plasminogen.
Aminocaproic acid is rapidly and completely absorbed from the GI tract; peak plasma concentrations are attained within about 1 hour following a 5-g oral dose. Plasma concentrations may be higher in patients with severe renal impairment. After prolonged administration, aminocaproic acid distributes through extravascular as well as intravascular compartments, penetrating human red blood cells and other body cells.
The major portion of aminocaproic acid is not metabolized. The drug is eliminated principally in the urine as unchanged drug (65%) and the adipic acid metabolite (11%). The terminal elimination half-life of aminocaproic acid is approximately 2 hours.
The drug is removed by hemodialysis and may be removed by peritoneal dialysis.
USES: This medication is used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This may cause serious bleeding after certain surgeries or in certain conditions (such as bleeding disorders, liver disease, cancer). Aminocaproic acid works by helping your blood clot normally.
It belongs to a class of drugs known as antifibrinolytics.
Generic name: aminocaproic acid
Pronunciation: (a-MEE-noe-ka-PROE-ik AS-id)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Aminocaproic Acid
Indications
The following indications are listed for Aminocaproic Acid:
- Hyperfibrinolysis-Induced Hemorrhage
- Postsurgical Hemorrhage
Also known as: Hyperfibrinolysis Induced Hemorrhage, Hyperfibrinolysis-Induced Bleeding, Postoperative Bleeding, Postoperative Hemorrhage.
Dosing
No dosing information is available for this tab.
Aminocaproic acid is administered orally or by IV infusion (after dilution). Rapid IV injection of the drug is not recommended since hypotension, bradycardia, and/or arrhythmia may result.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
*Active intravascular clotting process.
*When it is not clear whether hemorrhage is secondary to primary fibrinolysis or disseminated intravascular coagulation (DIC), the distinction must be made before aminocaproic acid is administered. Do not use without concomitant heparin therapy in patients with evidence of DIC.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects have included nausea, vomiting, cramping, abdominal pain, diarrhea, dizziness, malaise, dyspnea, nasal congestion, headache, edema, and pruritus.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy of aminocaproic acid in pediatric patients have not been established.
Aminocaproic acid injection contains benzyl alcohol as a preservative. Administration of injections preserved with benzyl alcohol has been associated with toxicity in neonates. Toxicity appears to have resulted from administration of large amounts (i.e., 100-400 mg/kg daily) of benzyl alcohol in these neonates. Each mL of aminocaproic acid injection in multiple-dose vials contains 9 mg of benzyl alcohol. Although use of drugs preserved with benzyl alcohol should be avoided in neonates whenever possible, the American Academy of Pediatrics (AAP) states that the presence of small amounts of the preservative in a commercially available injection should not proscribe its use when indicated in neonates.
Animal reproduction studies have not been conducted with aminocaproic acid. It is not known whether aminocaproic acid can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Aminocaproic acid should be given to a pregnant woman only if clearly needed.
It is not known whether aminocaproic acid is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.